NEUFORM PHARMACEUTICALS INC has a total of 24 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2016. It filed its patents most often in WIPO (World Intellectual Property Organization), China and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are TECNIMEDE SOCIEDADE TECNICO MEDICINAL S, TECNIMEDE SOC TECNICO-MEDICINAL S A and MADRIGAL PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | China | 5 | |
#3 | Australia | 3 | |
#4 | Canada | 3 | |
#5 | EPO (European Patent Office) | 3 | |
#6 | United States | 3 | |
#7 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Organic chemistry methods | |
#5 | Measuring electric variables | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Cheng Changfu | 21 |
#2 | Huang Chaoran | 21 |
#3 | Changfu Cheng | 3 |
#4 | Chaoran Huang | 3 |
Publication | Filing date | Title |
---|---|---|
EP3472155A1 | Deuterated compounds for treating pain | |
EP3394047A1 | Deuterated compounds for treating cancer and compositions and methods thereof | |
WO2017105881A1 | Deuterated compounds for treating pain | |
CN108699061A | For treating hematologic malignancies, inflammation and the deuterated compound of autoimmune disease | |
WO2017079003A1 | Deuterated compounds for treating blood cancers, and compositions and methods thereof | |
CN107207469A | For treat the deuterated compound of hematologic malignancies with and combinations thereof and method |